Alligator is a clinical-stage biotechnology company focused on the CD40 receptor with a validated approach that promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment. The company develops products using technology platforms including ALLIGATOR-GOLD, ALLIGATOR-FAB, FIND, and RUBY, with collaboration agreements with Aptevo Therapeutics, Orion Corporation, BioArctic AB, and Abclon Inc.
Cyborg Score Rationale
Early-stage clinical biotech with significant clinical promise in mitazalimab but facing severe financial distress. Stock has collapsed 98%+ in the past year, recent capital raises indicate liquidity concerns, and company is burning cash. However, Phase 2 survival data in pancreatic cancer suggests meaningful clinical potential.
Top Insights
Mitazalimab has demonstrated unprecedented 30-month survival data in Phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer
Stock has declined 98.22% over the past 365 days, indicating severe investor confidence erosion
Company conducted a rights issue during October-December 2025 issuing 226.7 million warrants and 18.6 million additional warrants in January 2026, signaling urgent capital needs
Pipeline includes multiple clinical and preclinical assets: Mitazalimab (Phase 2), ATOR-4066 (preclinical), ALG.APV-527 (Phase 1), and ATOR-1017 (Phase 1)
Named Competitors
Opdivo (Nivolumab) — PD-1 checkpoint inhibitor for immunotherapy
KEYTRUDA (Pembrolizumab) — PD-1 inhibitor for immuno-oncology